| Abstrakt: |
Objective: This case–control study aimed to investigate the diagnostic accuracy of salivary interleukin (IL)‐1β, IL‐10, and IL‐1β/IL‐10 ratio to discriminate periodontitis from periodontal health and stable from unstable periodontitis. Methods: Saliva samples were collected from 135 (healthy on an intact periodontium = 45 [as healthy control], stable periodontitis = 39, and unstable periodontitis = 51) participants, and then clinical periodontal parameters were recorded. An enzyme‐linked immunosorbent assay was used to determine salivary levels of IL‐1β and IL‐10. Area under the curves (AUCs), sensitivity, and specificity of IL‐1β, IL‐10, and IL‐1β/IL‐10 were estimated to discriminate between groups. Result: The level of salivary IL‐1β was significantly higher in unstable periodontitis than in stable periodontitis and healthy control groups (426 ± 59, 247 ± 55, and 204 ± 36 pg/ml [picograms per milliliter], respectively). While the level of salivary IL‐10 was significantly higher in the control group (360.7 ± 80.5 pg/ml) than unstable periodontitis group (146.92 ± 1.8 pg/ml), no significant difference was found between the control and stable periodontitis (317.04 ± 59.8 pg/ml) groups. IL‐1β, IL‐10, and IL‐1β/IL‐10 had significant diagnostic accuracy for differentiating healthy control from unstable periodontitis (AUCs = 0.99, 0.96, and 1; sensitivity = 0.98,1, and 1; specificity = 0.95, 0.95, and 1, respectively). Similarly, they showed significant diagnostic accuracy in distinguishing unstable from stable periodontitis (AUCs = 0.98, 0.99, and 1; sensitivity = 0.94, 1, and 1; specificity = 0.94, 0.97, and 1, respectively). Conclusion: Salivary IL‐1β, IL‐10, and IL‐1β/IL‐10 have a high potential to discriminate healthy control from periodontitis and stable from unstable periodontitis. Trial Registration: ClinicalTrials.gov identifier: NCT05722613 [ABSTRACT FROM AUTHOR] |
Plný text